突发！北大医药董事长被刑拘

Core Points - The chairman and president of Beijing University Pharmaceutical Co., Ltd., Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties [1] - The company asserts that its control has not changed, the board of directors is functioning normally, and its financial and operational management remains stable [1] - The company has undergone changes in actual control, with Peking University no longer being the actual controller since December 2022, and plans to gradually complete the renaming of the company and its subsidiaries to reflect this change [2] Company Structure and Operations - Xu Xiren became the actual controller of Beijing University Pharmaceutical by acquiring 22.22% of the shares through a symbolic purchase and debt acquisition, making him the key figure in the company's management [3] - The company specializes in drug research, production, and sales, recognized as a national innovative pilot enterprise and a key high-tech enterprise under the national torch program [3] - The company’s subsidiary, Beijing Beiyi Pharmaceutical Co., Ltd., heavily relies on business cooperation with Peking University International Hospital, which is its largest client, accounting for 78.15% of the company's drug distribution revenue in 2024 [2] Business Risks - The termination of business cooperation with Peking University International Hospital in May 2025 poses significant risks, including the potential cessation of main business operations and challenges in finding alternative business partners [2] - Xu Xiren controls 59 companies across various sectors, indicating a diversified business portfolio, which may influence the strategic direction of Beijing University Pharmaceutical [4]